Stock Research for CLSN


Featured Broker: Ally Invest

Get the due diligence for another stock.


CLSN Stock Chart & Research Data

The CLSN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLSN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CLSN Due diligence Resources & Stock Charts

The CLSN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLSN Detailed Price Forecast - CNN Money CNN View CLSN Detailed Summary - Google Finance
Yahoo View CLSN Detailed Summary - Yahoo! Finance Zacks View CLSN Stock Research & Analysis -

Stock Analysis

TradeIdeas View CLSN Trends & Analysis - Trade-Ideas Barrons View CLSN Major Holders - Barrons
NASDAQ View CLSN Call Transcripts - NASDAQ Seeking View CLSN Breaking News & Analysis - Seeking Alpha
Spotlight View CLSN Annual Report - OTC Report View CLSN OTC Short Report -
TradeKing View CLSN Fundamentals - TradeKing Charts View CLSN SEC Filings - Bar Chart
WSJ View Historical Prices for CLSN - The WSJ Morningstar View Performance/Total Return for CLSN - Morningstar
MarketWatch View the Analyst Estimates for CLSN - MarketWatch CNBC View the Earnings History for CLSN - CNBC
StockMarketWatch View the CLSN Earnings - StockMarketWatch MacroAxis View CLSN Buy or Sell Recommendations - MacroAxis
Bullish View the CLSN Bullish Patterns - American Bulls Short Pains View CLSN Short Pain Metrics -

Social Media Mentions

StockTwits View CLSN Stock Mentions - StockTwits PennyStocks View CLSN Stock Mentions - PennyStockTweets
Twitter View CLSN Stock Mentions - Twitter Invest Hub View CLSN Investment Forum News - Investor Hub
Yahoo View CLSN Stock Mentions - Yahoo! Message Board Seeking Alpha View CLSN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CLSN - Insider Cow View Insider Transactions for CLSN - Insider Cow
CNBC View CLSN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLSN - OTC Markets
Yahoo View Insider Transactions for CLSN - Yahoo! Finance NASDAQ View Institutional Holdings for CLSN - NASDAQ

Stock Charts

FinViz View CLSN Stock Insight & Charts - StockCharts View CLSN Investment Charts -
BarChart View CLSN Stock Overview & Charts - BarChart Trading View View CLSN User Generated Charts - Trading View

Latest Financial News for CLSN

Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations
Posted on Monday September 17, 2018

Celsion Corporation (CLSN), an oncology drug development company, today announced the appointment of Marianne Lambertson as Vice President of Communications and Investor Relations effective September 17, 2018. Ms. Lambertson most recently held the position of Vice President, Corporate Communications, Investor Relations/Public Relations at Verastem Oncology, a development-stage biopharmaceutical company.

The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Posted on Sunday September 16, 2018

Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients
Posted on Thursday September 06, 2018

Celsion Corporation (CLSN), an oncology drug development company, today announced it has begun dosing patients in the recently initiated OVATION II Study, the Company's randomized, Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer as an adjuvant to chemotherapy current standard of care. GEN-1, designed using Celsion's proprietary TheraPlas platform technology, is an interleukin-12 (IL-12) DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. "In previous studies, GEN-1 was shown to be well tolerated at doses up to 79 mg/m2 with meaningful, dose-dependent, pro-immune clinical activity,” said Dr. Nicholas Borys, Celsion's senior vice president and chief medical officer. “The overall median progression-free survival (PFS) in the first OVATION Study recently reached 24 months among patients treated per protocol.

Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Posted on Wednesday September 05, 2018

Celsion Corporation (CLSN), an oncology drug development company, today announced that it has reached its enrollment objective of 550 patients in the Company's pivotal, Phase III OPTIMA Study, a multinational, randomized, double-blind, placebo-controlled clinical trial of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. The OPTIMA Study's design and statistical plan incorporates two pre-planned interim efficacy analyses by the study’s Data Monitoring Committee (DMC), and the first interim analysis is expected to occur in the first half of 2019.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.